Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

octapharma (ip) sprl, brusel array - 3531 lidskÝ koagulaČnÍ faktor viii - prášek a rozpouštědlo pro injekční roztok - 100iu/ml - koagulaČnÍ faktor viii

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

octapharma (ip) sprl, brusel array - 3531 lidskÝ koagulaČnÍ faktor viii - prášek a rozpouštědlo pro injekční roztok - 50iu/ml - koagulaČnÍ faktor viii

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

octapharma (ip) sprl, brusel array - 3531 lidskÝ koagulaČnÍ faktor viii - prášek a rozpouštědlo pro injekční roztok - 200iu/ml - koagulaČnÍ faktor viii

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

octapharma (ip) sprl, brusel array - 3531 lidskÝ koagulaČnÍ faktor viii - prášek a rozpouštědlo pro injekční roztok - 100iu/ml - koagulaČnÍ faktor viii

Evropská unie - čeština - EMA (European Medicines Agency)

eli lilly and company limited  - fentanyl - nervový systém - psi - pro kontrolu bolesti spojené s ortopedickou operací a operací měkkých tkání u psů.

Evropská unie - čeština - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, typ 2 - léky užívané při diabetu - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Evropská unie - čeština - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, typ 2 - léky užívané při diabetu - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

sanofi pasteur, lyon array - 1566 difterickÝ toxoid; 4583 tetanickÝ toxoid; 14654 pertusovÝ toxoid; 14655 filamentÓznÍ hemaglutinin dÁvivÉho kaŠle; 14656 pertaktin; 18808 fimbrie typ 2 a 3; 14152 inaktivovanÝ virus poliomyelitidy typ 1; 14153 inaktivovanÝ virus poliomyelitidy typ 2; 14154 inaktivovanÝ virus poliomyelitidy typ 3 - injekční suspenze v předplněné injekční stříkačce - difterie-pertuse-poliomyelitida-tetanus

Evropská unie - čeština - EMA (European Medicines Agency)

virbac s.a. - recombinant omega interferon of feline origin - immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. in cats infected by fiv, mortality was low (5%) and was not influenced by the treatment.

Evropská unie - čeština - EMA (European Medicines Agency)

merck sharp dohme ltd - lidským papilomavirem typu 6 l1 proteinu lidského papilomaviru typu 11 l1 proteinu lidského papilomaviru typu 16 l1 proteinu hpv typu 18 l1 protein - papillomavirus infections; uterine cervical dysplasia; condylomata acuminata; immunization - vakcíny - přípravek silgard je vakcína k použití od věku 9 let k prevenci:premaligních genitálních lézí (cervikálních, vulválních a vaginálních), premaligních análních lézí, cervikálních karcinomů a análních karcinomů v příčinné souvislosti s určitou onkogenní lidským papilomavirem (hpv) typů;genitální bradavice (condyloma acuminata) v příčinné souvislosti s specifickými typy hpv. viz kapitoly 4. 4 a 5. 1 pro důležité informace o datech, které tuto indikaci podporují. použití přípravku silgard musí být v souladu s oficiálními doporučeními.